Condition

Primary Biliary Cholangitis clinical trials and research

• 16Clinical trials
• 3NIH research projects
• 30Countries

Newest Primary Biliary Cholangitis clinical trials

All recruiting trials (16)

• Seladelpar and Cilofexor in Primary Biliary Cholangitis (PBC)

  This study tests whether combining seladelpar with cilofexor helps people with primary biliary cholangitis more than seladelpar alone or placebo.

  Recruiting at 4 sites Phase 2 Gilead Sciences · Colorado Springs, Colorado and 3 other locations · NCT07841977

• Austrian PBC Registry

  This registry follows adults with primary biliary cholangitis in Austrian centers to see how the disease develops over time and how biomarkers relate to complications and symptoms.

  Recruiting Medical University of Vienna · Klagenfurt, Carinthia and 10 other locations · NCT07598669

• Biochemical response and health outcomes in people with primary biliary cholangitis

  We will follow adults with primary biliary cholangitis who are taking ursodeoxycholic acid (UDCA) to see if their alkaline phosphatase levels after treatment predict how long they stay free of complications.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07449793

• Saroglitazar Magnesium for PBC with incomplete UDCA response or intolerance

  This study tests whether Saroglitazar Magnesium can help people with primary biliary cholangitis who still have high alkaline phosphatase despite UDCA or cannot take UDCA.

  Recruiting Phase 3 Zydus Therapeutics Inc. · Lakewood Rch, Florida · NCT07424677

• CS0159 for primary biliary cholangitis when UDCA doesn't work or isn't tolerated.

  This test tries to see if taking CS0159 once daily helps adults with primary biliary cholangitis who have an inadequate response to or cannot tolerate UDCA.

  Recruiting at 39 sites Phase 3 Cascade Pharmaceuticals, Inc · Hefei, Anhui and 41 other locations · NCT07282353

• Saroglitazar Magnesium-V as add-on therapy for primary biliary cholangitis

  This trial tests whether Saroglitazar Magnesium-V, compared with placebo, can improve long-term clinical outcomes in adults with primary biliary cholangitis who are on UDCA.

  Recruiting at 3 sites Phase 3 Zydus Therapeutics Inc. · Marietta, Georgia and 2 other locations · NCT07216235

• LEOPARD: Predicting liver transplant dropout with AI in European patients

  This project tests new AI-based models to predict which liver transplant candidates are at highest risk of dropout or death while on the waitlist.

  Recruiting at 4 sites Assistance Publique - Hôpitaux de Paris · Ghent, Belgium and 7 other locations · NCT06723275

• Collecting data to improve liver transplantation predictions

  This study is trying to use AI to better predict which liver transplant candidates are at risk of dropping out of the waitlist, so that more people can get fair access to transplants across Europe.

  Recruiting at 53 sites Assistance Publique - Hôpitaux de Paris · Vienna and 52 other locations · NCT06675604

• Using Fenofibrate to treat Primary Biliary Cholangitis

  This study tests if Fenofibrate can safely help people with Primary Biliary Cholangitis manage their liver condition over a long time.

  Recruiting Phase 2/3 Xijing Hospital of Digestive Diseases · Xi'an, Shaanxi · NCT06365424

• Evaluating Seladelpar for Primary Biliary Cholangitis with Cirrhosis

  This study is testing if a new medication called Seladelpar can help adults with Primary Biliary Cholangitis and cirrhosis feel better and improve their liver health.

  Recruiting at 215 sites Phase 3 Gilead Sciences · Birmingham, Alabama and 217 other locations · NCT06051617

• Program to find patients with Primary Biliary Cholangitis who have been lost to follow-up

  This program is trying to find and help patients with Primary Biliary Cholangitis who have fallen out of regular care to improve their health and treatment outcomes.

  Recruiting Hospital Mutua de Terrassa · Terrassa, Barcelona · NCT05919433

• Combining fenofibrate with ursodeoxycholic acid for treating primary biliary cholangitis

  This study is testing if adding fenofibrate to the usual treatment with ursodeoxycholic acid can help people with primary biliary cholangitis who aren't getting better with just ursodeoxycholic acid.

  Recruiting at 6 sites Phase 3 Xijing Hospital of Digestive Diseases · Lanzhou, Gansu and 6 other locations · NCT05751967

• Fenofibrate treatment for patients with compensated cirrhosis and primary biliary cholangitis

  This study is testing if fenofibrate can help people with compensated cirrhosis caused by primary biliary cholangitis feel better when added to their current treatment.

  Recruiting at 11 sites Phase 2/3 Xijing Hospital of Digestive Diseases · Beijing, Beijing Municipality and 11 other locations · NCT05749822

• National database for patients with Primary Biliary Cholangitis in Italy

  This study is creating a national database for people in Italy with Primary Biliary Cholangitis to better understand the disease and improve treatment options.

  Recruiting at 50 sites University of Milano Bicocca · Ancona and 54 other locations · NCT05151809

• Reducing medication regimen for UDCA in PBC patients

  This study is testing if lowering the dose of a medication called UDCA can still help people with Primary Biliary Cholangitis who are doing well on their current treatment.

  Recruiting Phase 4 Peking Union Medical College Hospital · Beijing · NCT04650243

• Swiss Primary Biliary Cholangitis Cohort

  This project will collect medical information and yearly blood samples from adults in Switzerland with primary biliary cholangitis to help understand its course and outcomes.

  Recruiting at 13 sites Fondazione Epatocentro Ticino · Lugano, Canton Ticino and 12 other locations · NCT03146910

NIH-funded research (3)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Role of MAIT Cells in Primary Biliary Cholangitis (PBC)

  This grant investigates how MAIT immune cells contribute to the autoimmune liver disease PBC and what that means for future therapies.

  NIH research La Jolla Institute for Immunology · La Jolla, United States · NIH-11451080

• P2RY8 in liver blood vessel cells and B cells in autoimmune liver disease

  This grant explores how a liver blood-vessel cell signal (P2RY8) might influence B cells and antibodies in primary biliary cholangitis, a liver autoimmune disease.

  NIH research Yale University · New Haven, United States · NIH-11440250

• Understanding the causes of Primary Biliary Cholangitis

  This study is looking into how Primary Biliary Cholangitis (PBC) works in the body, focusing on the immune system and environmental influences, to help create better, personalized treatments for people living with this liver disease.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-10747958

Related topics

Quick answers

How many Primary Biliary Cholangitis clinical trials are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 30 countries. The most sites are in China (7 trials), Italy (4 trials), United States (4 trials), Austria (3 trials), Belgium (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 5, Phase 2/3: 2, Phase 2: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →